The AEZS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AEZS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AEZS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View AEZS Detailed Price Forecast - CNN Money||View AEZS Detailed Summary - Google Finance|
|View AEZS Detailed Summary - Yahoo! Finance||View AEZS Stock Research & Analysis - Zacks.com|
|View AEZS Trends & Analysis - Trade-Ideas||View AEZS Major Holders - Barrons|
|View AEZS Call Transcripts - NASDAQ||View AEZS Breaking News & Analysis - Seeking Alpha|
|View AEZS Annual Report - CompanySpotlight.com||View AEZS OTC Short Report - OTCShortReport.com|
|View AEZS Fundamentals - TradeKing||View AEZS SEC Filings - Bar Chart|
|View Historical Prices for AEZS - The WSJ||View Performance/Total Return for AEZS - Morningstar|
|View the Analyst Estimates for AEZS - MarketWatch||View the Earnings History for AEZS - CNBC|
|View the AEZS Earnings - StockMarketWatch||View AEZS Buy or Sell Recommendations - MacroAxis|
|View the AEZS Bullish Patterns - American Bulls||View AEZS Short Pain Metrics - ShortPainBot.com|
|View AEZS Stock Mentions - StockTwits||View AEZS Stock Mentions - PennyStockTweets|
|View AEZS Stock Mentions - Twitter||View AEZS Investment Forum News - Investor Hub|
|View AEZS Stock Mentions - Yahoo! Message Board||View AEZS Stock Mentions - Seeking Alpha|
|View Insider Transactions for AEZS - SECform4.com||View Insider Transactions for AEZS - Insider Cow|
|View AEZS Major Holdings Summary - CNBC||View Insider Disclosure for AEZS - OTC Markets|
|View Insider Transactions for AEZS - Yahoo! Finance||View Institutional Holdings for AEZS - NASDAQ|
|View AEZS Stock Insight & Charts - FinViz.com||View AEZS Investment Charts - StockCharts.com|
|View AEZS Stock Overview & Charts - BarChart||View AEZS User Generated Charts - Trading View|
Aeterna Zentaris Provides Corporate Update
Posted on Thursday June 06, 2019
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it is reducing the size of its German workforce and operations to more closely reflect the Company's ongoing commercial activities in Frankfurt. The Company is also providing an update on the previously disclosed securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the Company. The lawsuit alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.
Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
Posted on Wednesday May 08, 2019
CHARLESTON, S.C., May 08, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the.
Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates
Posted on Tuesday May 07, 2019
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -450.00% and -99.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris: 1Q Earnings Snapshot
Posted on Tuesday May 07, 2019
The Summerville, South Carolina-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs and research and development costs, came to 14 cents per share. The drug ...